secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001193805-22-001712
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus' COVID-19 vaccine ARCT-154 enters Phase III trial in Japan; CSL collaboration effective
--------------------------------------------------------------------------------

- Meiji Seika Pharma initiated a Phase III trial of ARCT-154 (self-amplifying mRNA COVID-19 vaccine) in Japan with 780 participants; half receive ARCT-154 as a booster.
- The trial will evaluate non-inferiority of ARCT-154 as a booster series compared to a comparator group.
- CSL Seqirus announced that the previously disclosed collaboration agreement (Nov 1, 2022) with Arcturus became effective on December 8, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522001712/0001193805-22-001712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522001712/e618105_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-22-001712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer